Reporting Accountant Services for the acquisition and re-admission onto AIM.
CRISM Therapeutics Corporation, a pharmaceutical company, specialises in drug delivery technology – notably developing ChemoSeed, a polymer that administers chemotherapy directly to tumours – as well as formulation and consultancy services to enhance the bioavailability of poorly soluble drugs.
The HaysMac team provided reporting accountant services for CRISM Therapeutics Corporation’s acquisition of Extruded Pharmaceuticals Limited and their re-admission onto AIM. The issuance of 23,939,986 new ordinary shares in CRISM Therapeutics Corporation, formerly known as Amur Minerals Corporation, this transaction was valued at £5.5 million, a significant shift for CRISM from mineral exploration to pharmaceutical advancements.
HaysMac delivered comprehensive due diligence services, including reviewing financial statements. We ensured that all regulatory requirements were met, facilitating a smooth acquisition and successful re-admission onto AIM.
Commenting on the transaction, Ian Cliffe, Partner, said: “We are delighted to have supported CRISM on this acquisition. This deal represents a significant milestone for the company, and we are proud to have played a role in facilitating their strategic transition into the pharmaceutical sector. Our team is confident that CRISM’s innovative approach to cancer treatment will yield substantial benefits for patients and stakeholders alike.”
